1.Sales and profit
See section β- Alumis Inc. had $24.1M of revenue in fiscal 2025.
- Its operating margin was β1,886.9%: of every 100 in sales, about β1,887 is left after running the business.
- Alumis Inc. lost $243M in fiscal 2025.
Alumis Inc.
ALMS Nasdaq Pharmaceutical Preparations Financials FY2023βFY2025
Alumis Inc. had $24.1M of revenue in fiscal 2025.
Last close Β· Oct 23, 2026
$6.78
0.6%KIRAβs summary AI analyst
Hi! I read Alumis Inc.βs latest annual report (fiscal 2025). Here is what stands out:
3 to watch
2.Cash and shareholders
See section β- Free cash flow was β$370M in fiscal 2025, β1,539.2% of revenue.
- Alumis Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 200.0%.
- In the last 12 months, insiders bought $45.0M and sold $1.5M of shares on the open market.
Alumis Inc. in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β1,011.7%
No. It lost money last year.
Weak
Does profit turn into cash?
β1,539.2%
No. It spent more cash than it brought in.
For information
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$866M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$3.66 EPS (TTM)
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Revenue and margins
KIRA Β· Alumis Inc. had $24.1M of revenue in fiscal 2025. Its operating margin was β1,886.9%: of every 100 in sales, about β1,887 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
FY23
Revenue β
FY24
Revenue β
FY25
Revenue $24.1M
Revenue
Q3 '23
Revenue β
Q4 '23
Revenue β
Q1 '24
Revenue β
Q2 '24
Revenue β
Q3 '24
Revenue β
Q4 '24
Revenue β
Q1 '25
Revenue $17.4M
Q2 '25
Revenue $2.7M
Q3 '25
Revenue $2.1M
Q4 '25
Revenue $1.9M
Q1 '26
Revenue $1.7M
Q2 '26
Revenue $1.7M
Margins, % of revenue
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β1,886.9%
Net β1,011.7%
FCF β1,539.2%
Gross
Operating
Net
FCF
Margins, % of revenue
Q3 '23
Gross β
Operating β
Net β
FCF β
Q4 '23
Gross β
Operating β
Net β
FCF β
Q1 '24
Gross β
Operating β
Net β
FCF β
Q2 '24
Gross β
Operating β
Net β
FCF β
Q3 '24
Gross β
Operating β
Net β
FCF β
Q4 '24
Gross β
Operating β
Net β
FCF β
Q1 '25
Gross β
Operating β583.9%
Net β569.1%
FCF β462.3%
Q2 '25
Gross β
Operating β5,271.5%
Net 2,225.1%
FCF β4,012.3%
Q3 '25
Gross β
Operating β5,580.4%
Net β5,360.7%
FCF β5,368.3%
Q4 '25
Gross β
Operating β4,999.7%
Net β4,817.6%
FCF β3,727.7%
Q1 '26
Gross β
Operating β5,652.4%
Net β5,344.8%
FCF β5,011.3%
Q2 '26
Gross β
Operating β8,956.4%
Net β8,557.2%
FCF β4,918.0%
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· Alumis Inc. lost $243M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
FY23
Net income β$155M
FY24
Net income β$294M
FY25
Net income β$243M
Net income
Q3 '23
Net income β$43.4M
Q4 '23
Net income β$39.3M
Q1 '24
Net income β$49.8M
Q2 '24
Net income β$56.5M
Q3 '24
Net income β$93.1M
Q4 '24
Net income β$94.8M
Q1 '25
Net income β$99.0M
Q2 '25
Net income $59.3M
Q3 '25
Net income β$111M
Q4 '25
Net income β$92.9M
Q1 '26
Net income β$93.1M
Q2 '26
Net income β$142M
Diluted EPS
FY23
Diluted EPS β$72.08
FY24
Diluted EPS β$10.38
FY25
Diluted EPS β$2.86
Diluted EPS
Q3 '23
Diluted EPS β$19.76
Q4 '23
Diluted EPS β
Q1 '24
Diluted EPS β$21.03
Q2 '24
Diluted EPS β$23.10
Q3 '24
Diluted EPS β$1.73
Q4 '24
Diluted EPS $35.48
Q1 '25
Diluted EPS β$1.82
Q2 '25
Diluted EPS $0.77
Q3 '25
Diluted EPS β$1.06
Q4 '25
Diluted EPS β$0.75
Q1 '26
Diluted EPS β$0.74
Q2 '26
Diluted EPS β$1.11
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
KIRA Β· Free cash flow was β$370M in fiscal 2025, β1,539.2% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
FY23
Free cash flow β$134M
FY24
Free cash flow β$257M
FY25
Free cash flow β$370M
Free cash flow
Q3 '23
Free cash flow β$35.4M
Q4 '23
Free cash flow β$34.9M
Q1 '24
Free cash flow β$44.4M
Q2 '24
Free cash flow β$52.7M
Q3 '24
Free cash flow β$84.5M
Q4 '24
Free cash flow β$75.1M
Q1 '25
Free cash flow β$80.4M
Q2 '25
Free cash flow β$107M
Q3 '25
Free cash flow β$111M
Q4 '25
Free cash flow β$71.9M
Q1 '26
Free cash flow β$87.2M
Q2 '26
Free cash flow β$81.7M
Cash from operations vs capital spending
FY23
Cash from operations β$130M
Capital spending $4.5M
FY24
Cash from operations β$255M
Capital spending $1.7M
FY25
Cash from operations β$370M
Capital spending $0.7M
Cash from operations
Capital spending
Cash from operations vs capital spending
Q3 '23
Cash from operations β$33.2M
Capital spending $2.2M
Q4 '23
Cash from operations β$33.7M
Capital spending $1.2M
Q1 '24
Cash from operations β$44.3M
Capital spending $0.2M
Q2 '24
Cash from operations β$52.3M
Capital spending $0.4M
Q3 '24
Cash from operations β$83.8M
Capital spending $0.8M
Q4 '24
Cash from operations β$74.8M
Capital spending $0.4M
Q1 '25
Cash from operations β$80.4M
Capital spending $0.0M
Q2 '25
Cash from operations β$106M
Capital spending $0.6M
Q3 '25
Cash from operations β$111M
Capital spending $0.0M
Q4 '25
Cash from operations β$71.9M
Capital spending $0.0M
Q1 '26
Cash from operations β$87.1M
Capital spending $0.2M
Q2 '26
Cash from operations β$81.5M
Capital spending $0.2M
Cash from operations
Capital spending
Dividends, buybacks and share count
KIRA Β· Alumis Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 200.0%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
FY23
Dividends β
Buybacks $0.1M
FY24
Dividends β
Buybacks $0.0M
FY25
Dividends β
Buybacks $0.0M
Dividends
Buybacks
Dividends and buybacks
Q3 '23
Dividends β
Buybacks $0.0M
Q4 '23
Dividends β
Buybacks $0.0M
Q1 '24
Dividends β
Buybacks β
Q2 '24
Dividends β
Buybacks β
Q3 '24
Dividends β
Buybacks β
Q4 '24
Dividends β
Buybacks $0.0M
Q1 '25
Dividends β
Buybacks β
Q2 '25
Dividends β
Buybacks β
Q3 '25
Dividends β
Buybacks $0.0M
Q4 '25
Dividends β
Buybacks $0.0M
Q1 '26
Dividends β
Buybacks β
Q2 '26
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY23
Diluted shares 0.00B
FY24
Diluted shares 0.03B
FY25
Diluted shares 0.09B
Insider trades
KIRA Β· In the last 12 months, insiders bought $45.0M and sold $1.5M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$45.0M
4 insiders
Sold, 12 months
$1.5M
7 insiders
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Srinivas AkkarajuDirector | Sold | 96,131 | $10.55 | $1.0M | Form 4 |
| Sep 8, 2026 | Srinivas AkkarajuDirector | Bought | 546,581 | $10.63 | $5.8M | Form 4 |
| Sep 4, 2026 | Srinivas AkkarajuDirector | Bought | 220,070 | $11.17 | $2.5M | Form 4 |
| Aug 3, 2026 | David M GoldsteinChief Scientific Officer | Sold | 2,596 | $26.37 | $0.1M | Form 4 |
| Aug 3, 2026 | Sanam PangaliChief Legal Officer | Sold | 1,364 | $26.37 | $0.0M | Form 4 |
| Aug 3, 2026 | Roy C. HardimanChief Business & Strategy Ofcr | Sold | 2,692 | $26.37 | $0.1M | Form 4 |
| Aug 3, 2026 | Mark Christopher BradleyChief Development Officer | Sold | 2,572 | $26.37 | $0.1M | Form 4 |
| Aug 3, 2026 | Jorn DrappaChief Medical Officer | Sold | 2,447 | $26.37 | $0.1M | Form 4 |
| Aug 3, 2026 | John R. SchroerChief Financial Officer | Sold | 3,282 | $26.37 | $0.1M | Form 4 |
| Jul 6, 2026 | Sanam PangaliChief Legal Officer | Sold | 5,000 | $28.00 | $0.1M | Form 4 |
| Jan 9, 2026 | Srinivas AkkarajuDirector | Bought | 588,235 | $17.00 | $10.0M | Form 4 |
| Jan 8, 2026 | James B. TananbaumDirector, 10% owner | Bought | 411,764 | $17.00 | $7.0M | Form 4 |
| Jan 8, 2026 | Foresite Labs Fund I, L.P.10% owner | Bought | 411,764 | $17.00 | $7.0M | Form 4 |
| Dec 5, 2025 | Srinivas AkkarajuDirector | Bought | 186,377 | $9.84 | $1.8M | Form 4 |
| Dec 4, 2025 | Srinivas AkkarajuDirector | Bought | 66,027 | $8.18 | $0.5M | Form 4 |
| Dec 3, 2025 | Srinivas AkkarajuDirector | Bought | 100,000 | $7.75 | $0.8M | Form 4 |
| Dec 2, 2025 | Srinivas AkkarajuDirector | Bought | 96,000 | $7.55 | $0.7M | Form 4 |
| Dec 1, 2025 | Srinivas AkkarajuDirector | Bought | 86,350 | $7.46 | $0.6M | Form 4 |
| Nov 28, 2025 | Srinivas AkkarajuDirector | Bought | 38,702 | $7.64 | $0.3M | Form 4 |
| Nov 26, 2025 | Srinivas AkkarajuDirector | Bought | 48,537 | $7.64 | $0.4M | Form 4 |
| Nov 21, 2025 | Foresite Labs Affiliates 2021, LLC10% owner | Bought | 72,212 | $7.38 | $0.5M | Form 4 |
| Nov 20, 2025 | Srinivas AkkarajuDirector | Bought | 125,743 | $7.20 | $0.9M | Form 4 |
| Nov 19, 2025 | Srinivas AkkarajuDirector | Bought | 137,772 | $6.56 | $0.9M | Form 4 |
| Nov 19, 2025 | James B. TananbaumDirector, 10% owner | Bought | 190,500 | $6.56 | $1.2M | Form 4 |
| Nov 18, 2025 | Srinivas AkkarajuDirector | Bought | 102,652 | $6.05 | $0.6M | Form 4 |
| Nov 18, 2025 | James B. TananbaumDirector, 10% owner | Bought | 117,374 | $6.19 | $0.7M | Form 4 |
| Nov 17, 2025 | Srinivas AkkarajuDirector | Bought | 914 | $5.51 | $0.0M | Form 4 |
| Nov 17, 2025 | James B. TananbaumDirector, 10% owner | Bought | 200,000 | $5.59 | $1.1M | Form 4 |
| Nov 13, 2025 | Srinivas AkkarajuDirector | Bought | 276,179 | $5.25 | $1.4M | Form 4 |
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Alumis Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
FY23
Cash $49.0M
Debt β
FY24
Cash $288M
Debt β
FY25
Cash $309M
Debt β
Cash
Debt
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $49.0M | $288M | $309M |
| Current ratio | 2.6x | 6.0x | 4.3x |
| Quick ratio | 2.6x | 6.0x | 4.3x |
| Total assets | $89.6M | $341M | $412M |
| Total liabilities | $53.5M | $80.9M | $111M |
| Shareholders' equity | β$339M | $260M | $301M |
| Net debt (β = net cash) | β | β | β |
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
FY23
Return on capital β
Return on equity β
Return on assets β173.0%
FY24
Return on capital β
Return on equity β
Return on assets β136.7%
FY25
Return on capital β
Return on equity β86.7%
Return on assets β64.6%
Return on capital
Return on equity
Return on assets
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 |
| Accruals ratio | β27.9% | β18.2% | 33.5% |
| Altman Z'' | β29.40 | β3.94 | β7.78 |
All figures
Every number, year by year.
3 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | β | β | $24.1M |
| Research and development | $138M | $266M | $386M |
| Operating income | β$158M | β$301M | β$454M |
| Pretax income | β | β$294M | β$252M |
| Income tax | $0.0M | $0.0M | β$8.6M |
| Net income | β$155M | β$294M | β$243M |
| Diluted EPS | β$72.08 | β$10.38 | β$2.86 |
| Diluted shares | 0.00B | 0.03B | 0.09B |
| Cash flow | |||
| Cash from operations | β$130M | β$255M | β$370M |
| Capital expenditure | $4.5M | $1.7M | $0.7M |
| Free cash flow | β$134M | β$257M | β$370M |
| Depreciation and amortization | $1.3M | $3.2M | $3.5M |
| Stock-based compensation | $8.6M | $19.5M | $43.5M |
| Share buybacks | $0.1M | $0.0M | $0.0M |
| Dividends and buybacks | $0.1M | $0.0M | $0.0M |
| Balance sheet | |||
| Cash and short-term investments | $49.0M | $288M | $309M |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M |
| Current assets | $53.4M | $306M | $318M |
| Current liabilities | $20.9M | $50.9M | $73.3M |
| Property and equipment, net | $22.4M | $21.0M | $18.2M |
| Total assets | $89.6M | $341M | $412M |
| Total liabilities | $53.5M | $80.9M | $111M |
| Shareholders' equity | β$339M | $260M | $301M |
| Margins | |||
| Operating margin | β | β | β1,886.9% |
| EBITDA margin | β | β | β1,872.4% |
| Net margin | β | β | β1,011.7% |
| FCF margin | β | β | β1,539.2% |
| Returns | |||
| Return on capital employed | β230.1% | β103.7% | β134.0% |
| Return on equity | β | β | β86.7% |
| Return on assets | β173.0% | β136.7% | β64.6% |
| Return on tangible equity | β | β113.1% | β80.8% |
| Growth | |||
| Share count change | β | 1,218.1% | 200.0% |
| Financial health | |||
| Current ratio | 2.6x | 6.0x | 4.3x |
| Quick ratio | 2.6x | 6.0x | 4.3x |
| Capital allocation | |||
| Capex / revenue | β | β | 2.7% |
| Stock comp / revenue | β | β | 181.0% |
| Quality scores | |||
| Altman Z'' | β29.4 | β3.9 | β7.8 |
| Accruals ratio | β27.9% | β18.2% | 33.5% |
Source: SEC EDGAR XBRL filings (CIK 0001847367). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.